• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?与依那西普治疗失败的类风湿关节炎患者相比，初治的类风湿关节炎患者对英夫利昔单抗的反应更好吗？
Ann Rheum Dis. 2004 May;63(5):607-8; author reply 608.
2
Etanercept and infliximab for rheumatoid arthritis.依那西普和英夫利昔单抗用于治疗类风湿关节炎。
Drug Ther Bull. 2001 Jul;39(7):49-52.
3
Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.类风湿关节炎患者的治疗：英夫利昔单抗治疗失败后改用依那西普的疗效
Arthritis Rheum. 2007 Apr 15;57(3):448-53. doi: 10.1002/art.22617.
4
[Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].[肿瘤坏死因子-α抑制剂治疗类风湿关节炎的临床经验]
Tidsskr Nor Laegeforen. 2005 Jun 16;125(12):1664-6.
5
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.依那西普和英夫利昔单抗的抗肿瘤坏死因子疗法可诱导类风湿关节炎关节中的巨噬细胞而非淋巴细胞发生凋亡的证据：扩展报告。
Arthritis Rheum. 2005 Jan;52(1):61-72. doi: 10.1002/art.20764.
6
Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.类风湿关节炎患者中，英夫利昔单抗或依那西普单药治疗与甲氨蝶呤或其他改善病情抗风湿药联合治疗的疗效比较：来自英国风湿病学会生物制剂登记处的结果
Arthritis Rheum. 2006 Jun;54(6):1786-94. doi: 10.1002/art.21830.
7
C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.C反应蛋白作为类风湿关节炎患者英夫利昔单抗治疗结果的预测指标：定义无反应亚型及随后对依那西普的反应
Arthritis Rheum. 2005 Jan;52(1):42-8. doi: 10.1002/art.20711.
8
Psoriatic arthritis patients doing better on infliximab than etanercept.
Rheumatology (Oxford). 2007 Apr;46(4):721-2. doi: 10.1093/rheumatology/kel454. Epub 2007 Feb 21.
9
Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.利妥昔单抗与依那西普联合治疗类风湿关节炎患者的安全性。
Rheumatology (Oxford). 2009 Apr;48(4):440-1. doi: 10.1093/rheumatology/ken491. Epub 2009 Jan 19.
10
Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.类风湿关节炎患者使用肿瘤坏死因子α拮抗剂治疗会诱导抗心磷脂抗体产生。
Ann Rheum Dis. 2004 Sep;63(9):1075-8. doi: 10.1136/ard.2003.018093. Epub 2004 Apr 5.

引用本文的文献

1
DAS steered therapy in clinical practice; cross-sectional results from the METEOR database.DAS指导临床实践中的治疗；来自METEOR数据库的横断面结果。
BMC Musculoskelet Disord. 2016 Jan 16;17:33. doi: 10.1186/s12891-016-0878-1.
2
Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.托珠单抗在类风湿关节炎患者常规临床治疗中的使用模式和剂量：ACT-LIFE研究
Rheumatol Int. 2015 Sep;35(9):1525-34. doi: 10.1007/s00296-015-3237-x. Epub 2015 Mar 13.
3
Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy.托珠单抗治疗类风湿关节炎：疗效、安全性及其在治疗中的地位。
Ther Adv Chronic Dis. 2013 Jan;4(1):15-21. doi: 10.1177/2040622312466908.
4
Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).类风湿关节炎中抗 TNF 药物转换的结果——基于芬兰生物治疗登记处（ROB-FIN）观察性数据的研究。
Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.
5
DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists.基于DAS-28的欧洲抗风湿病联盟（EULAR）反应及类风湿关节炎患者在肿瘤坏死因子拮抗剂之间转换时健康评估问卷（HAQ）的改善情况
BMC Musculoskelet Disord. 2009 Jul 23;10:91. doi: 10.1186/1471-2474-10-91.
6
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?对于先前抗 TNF 药物治疗失败的类风湿关节炎患者，哪些亚组患者从转换用利妥昔单抗治疗获益优于转换用其他抗 TNF 药物？
Ann Rheum Dis. 2010 Feb;69(2):387-93. doi: 10.1136/ard.2008.105064. Epub 2009 May 4.
7
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.类风湿关节炎患者初始肿瘤坏死因子抑制剂治疗失败后的治疗选择：一项批判性综述
Arthritis Res Ther. 2009;11 Suppl 1(Suppl 1):S1. doi: 10.1186/ar2666. Epub 2009 Apr 6.
8
Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.类风湿关节炎：对肿瘤坏死因子α拮抗剂反应不足患者的管理策略
Drugs. 2008;68(5):591-606. doi: 10.2165/00003495-200868050-00003.
9
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.在抗肿瘤坏死因子之间切换：试图解决一个复杂的问题。
Ann Rheum Dis. 2007 Jul;66(7):849-51. doi: 10.1136/ard.2007.069872.
10
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.开放标签、针对对依那西普反应不完全后改用英夫利昔单抗的类风湿性关节炎患者的试点方案：反向研究。
Ann Rheum Dis. 2007 Jul;66(7):893-9. doi: 10.1136/ard.2006.068304. Epub 2007 Apr 5.

Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?

作者信息

Yazici Y, Erkan D

出版信息

Ann Rheum Dis. 2004 May;63(5):607-8; author reply 608.

PMID:15082503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1754974/
Abstract
摘要